Vera says TRUTAKNA stabilized kidney function through two years
Vera Therapeutics said TRUTAKNA stabilized eGFR and prevented kidney-disease progression through two years in the final ORIGIN 3 analysis for IgA nephropathy.
The story
GlobeNewswire reported that Vera Therapeutics said its final efficacy analysis from the ORIGIN 3 study showed TRUTAKNA, also known as atacicept-vymj, stabilized estimated glomerular filtration rate and prevented progression of kidney disease through two years in patients with IgA nephropathy.
The update extends the study’s reported horizon to two years, shifting the focus from an interim efficacy readout to durability of renal outcomes.
For Vera, the direct commercial mechanism is TRUTAKNA’s potential positioning as a treatment for IgA nephropathy, with sustained eGFR and disease-progression outcomes relevant to the drug’s clinical and regulatory profile. No other company or revenue line is identified in the announcement, and no sales contribution or market-access detail is disclosed.
The evidence remains incomplete because the announcement provides conclusions but no underlying figures in the reported material. It is therefore not possible from this release to assess effect size, statistical significance, safety trade-offs, or how the result may affect the regulatory path.
The next useful evidence would be the full ORIGIN 3 dataset, including patient counts, comparator results, eGFR changes, progression events and safety findings, alongside any dated regulatory filing or agency decision. Vera’s subsequent disclosures should establish whether the two-year result changes the timing or scope of TRUTAKNA’s commercial launch opportunity.
Our read · Tue, Sep 15
The two-year ORIGIN 3 result moves the clinical read higher for VERA, but missing effect-size data keeps the commercial case conditional.
Why. The read-through is positive for VERA because durable eGFR stabilization and prevention of kidney-disease progression could strengthen TRUTAKNA’s clinical positioning in IgA nephropathy. The lack of numerical efficacy, safety and regulatory-timing detail prevents a stronger directional setup until the full dataset or a dated agency milestone clarifies the magnitude and commercial path.
Both cases
What could change this view: The setup fails if the full ORIGIN 3 results show a small or statistically weak treatment effect, unfavorable safety, or no clear regulatory path despite the announcement’s favorable wording.
Who reported it · 2
Keep reading
More on VERA
Guggenheim raises Vera Therapeutics stock price target on FDA approvalLatest on the Wire
Beijing plans to bar young red-chip firms from overseas listingsGerman producer prices jump 8.1% in October as industrial inflation acceleratesChina seeks protections to restart US private-equity investmentsAMD shares fall 11% after Hunterbrook warns over China linksWalmart raises full-year outlook as e-commerce wins shoppersContinue on the Wire →Latest on the Wire
Walmart raises full-year outlook as e-commerce wins shoppersContinuing claims rise as Goldman sees Fed hikes in December and MarchPIF Tower in Riyadh reportedly damaged in second Houthi attackTrump Media buys back $100 million of notes ahead of Nov. 30 cash demandContinue on the Wire →Top this week
Nvidia allies lobby board to bring back Jensen Huang as CEONvidia chair rules out Huang return as CEO after 75% sales outlookAnthropic Said to Guide IPO Pricing Above Market RangeNvidia interim CEO Colette Kress faces first earnings test after HuangNvidia CEO Jensen Huang reportedly resigns as US-China tensions riseAbout this report
Reported by GlobeNewswire as Vera Therapeutics Announces TRUTAKNA™ (atacicept-vymj) Stabilized eGFR and Prevented Kidney Disease Progression Through Two Years in ORIGIN 3 Final Efficacy Analysis in IgA Nephropathy
, . Who answers for this
2 reports from 2 publishers in this record. Closes are licensed end-of-day data from Databento; the move after a story is its first close against the close before it. How this is decided →
Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →